Skip to main content

Table 4 Visual acuity and central retinal thickness outcome by response to ranibizumab among nAMD subjects

From: Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects

   Responder (n = 54) Non-responder (n = 91) P b
Age   68.33 ± 6.47 69.56 ± 8.07 0.343
Smoking   15 (27.8) 35 (38.5) 0.191
Mean BCVA (logMAR)a Baseline 0.66 ± 0.27 0.51 ± 0.24 0.001*
3 months 0.57 ± 0.29 0.61 ± 0.24 0.304
6 months 0.43 ± 0.24 0.67 ± 0.28 < 0.001*
Mean CRT (μM)a Baseline 480.3 ± 153.78 326.9 ± 87.12 < 0.001c*
3 months 348.0 ± 114.79 355.8 ± 124.27 0.642
6 months 321.5 ± 98.73 390.8 ± 145.79 0.001*
Changes in BCVA (logMAR)a 3 months − 0.09 ± 0.20 0.10 ± 0.19 < 0.001*
6 months − 0.23 ± 0.22 0.16 ± 0.23 < 0.001*
Changes in CRT (μM)a 3 months − 132.3 ± 133.05 28.92 ± 83.39 < 0.001c*
6 months − 158.9 ± 132.02 63.96 ± 119.60 < 0.001c*
  1. Data are presented as percentages in parentheses
  2. CRT central retinal thickness, BCVA best-corrected visual acuity
  3. *Significant P value, P < 0.05
  4. aData presented as mean ± standard deviation (SD)
  5. bMann-Whitney U test
  6. CStudent’s t test